Clinical Trial


Schedules of Nab-Paclitaxel in Metastatic Breast Cancer


Brief description

Longer first line chemotherapy duration has recently been associated with a modest, but significant improvement in overall survival and a clinically meaningful and statistically significant improvement in progression-free survival, in metastatic breast cancer patients. Prolonging chemotherapy until disease progression, however, must be weighed against the detrimental effects of continuous chemotherapy delivery. The SNAP trial seeks to improve the tolerability of prolonged chemotherapy administration strategy by studying alternative treatment schedules, while preserving and possibly improving treatment efficacy in this disease setting. The availability of a new nanoparticle albumin-bound taxane, nab-Paclitaxel (Abraxane®), represents an opportunity to test this hypothesis. Nab-Paclitaxel has been developed in an attempt to reduce the toxicity associated with standard taxane administration (caused by the use of chemical solvents) while increasing antitumor efficacy. The SNAP randomized phase II trial evaluates three schedules of nab-Paclitaxel as prolonged chemotherapy administration strategy. Each of three arms will be compared to a historical reference of seven-month median progression-free survival (PFS) based on the most recent trial with docetaxel as control arm to determine whether any of the three arms are worthy of further investigation.

Keywords

  •   Metastatic Breastcancer

Sponsored By

International Breast Cancer Study Group

Unique Study ID

NCT01746225

Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

University of Liege
4000, Liège, Belgium
Distance from Current Trial is 0 miles

Annie Dubuisson, M.D.; Ph.D.

Universitaire Ziekenhuizen Leuven
4000, Liège, Belgium
Distance from Current Trial is 0 miles

No Investigator Listed

University of Liege
4000, Liège, Belgium
Distance from Current Trial is 0 miles
View All